Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its news flow reflects both its operating performance and corporate developments. Company announcements describe technologies that prioritize preservation and restoration of the patient’s own anatomy and leverage the natural healing response while minimizing long-term exposure to permanent synthetic materials.
News updates for TELA stock frequently include quarterly financial results, where the company reports revenue, gross profit, operating expenses, and net loss, along with commentary on demand for its OviTex and OviTex PRS reinforced tissue matrix products. These releases often discuss factors driving revenue, such as increased unit sales, new customers, international sales, and new product configurations, as well as changes in operating expenses and loss from operations.
Investors can also expect capital markets and financing news, including announcements of credit facilities, registered direct offerings of common stock and pre-funded warrants, and the issuance of warrants in connection with debt agreements. Such updates provide insight into TELA Bio’s liquidity, borrowing arrangements, and intended use of proceeds for sales and marketing, research and development, and other corporate purposes.
Another category of TELA Bio news involves corporate governance and leadership changes, such as appointments of new independent directors with experience in healthcare equity research and executive nursing leadership, as well as board resignations. The company also issues releases about participation in healthcare conferences and inducement grants of restricted stock units and stock options to newly hired employees under Nasdaq Listing Rule 5635(c)(4).
By following TELA Bio’s news feed, readers gain timely visibility into the company’s financial performance, product demand trends in soft-tissue reconstruction, capital-raising activities, and changes in board composition and employee equity incentives.
TELA Bio (NASDAQ:TELA) reported strong Q2 2025 financial results with revenue of $20.2 million, representing 26% year-over-year growth and 9% sequential growth. The company's OviTex and OviTex PRS products saw significant demand increases, with year-over-year revenue growth of 12% and 53% respectively.
The company appointed Jeffrey Blizard as President to strengthen commercial leadership and announced the European launch of OviTex Inguinal for robotic procedures. Despite a gross profit of $14.1 million (69.8% margin), TELA Bio recorded a net loss of $9.9 million, an improvement from the $12.6 million loss in Q2 2024.
TELA Bio reiterated its full-year 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth. The company ended Q2 with $35.0 million in cash and cash equivalents.
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants to fourteen new employees. The Compensation Committee approved restricted stock units covering 10,200 shares of common stock, granted on August 5, 2025.
These grants, made under Nasdaq Rule 5635(c)(4), are part of the employees' compensation packages and will vest equally over four years, contingent on continued employment with TELA Bio.
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on August 13th, 2025, at 10:00 am ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring management's discussion of financial results and a corporate update. Interested investors must register in advance or at least 15 minutes before the call. The webcast and replay will be accessible through the Events & Presentations section of TELA's investor website.
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on June 5th, 2025, at 11:05 am ET. Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at ir.telabio.com.
TELA Bio (NASDAQ: TELA), a medical technology company specializing in soft-tissue reconstruction solutions, has announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of restricted stock units (RSUs) covering 6,600 shares of common stock, awarded to twelve newly-hired employees with a grant date of May 5, 2025. These RSUs, granted under Nasdaq Rule 5635(c)(4), will vest in equal annual installments over a four-year period, contingent on continued employment with TELA Bio.
TELA Bio (TELA) reported Q1 2025 financial results with revenue of $18.5 million, representing 12% year-over-year growth and 5% sequential growth. The company's OviTex and OviTex PRS products saw revenue increases of 15% and 2% respectively. TELA Bio launched larger-sized OviTex PRS for plastic and reconstructive surgery.
Gross profit reached $12.5 million (67.6% margin), while operating expenses decreased to $22.9 million. The company reported a net loss of $11.3 million. Cash and equivalents stood at $42.8 million as of March 31, 2025. TELA Bio reiterated its 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth, with operating expenses expected to remain flat compared to 2024.